<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542254</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-009-2015</org_study_id>
    <secondary_id>2015-002536-41</secondary_id>
    <nct_id>NCT02542254</nct_id>
  </id_info>
  <brief_title>The Effects of RPL554 on Top of Standard COPD Reliever Medications</brief_title>
  <official_title>A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of RPL554 to standard reliever medications for chronic&#xD;
      obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a&#xD;
      randomised sequence:&#xD;
&#xD;
        1. salbutamol,&#xD;
&#xD;
        2. ipratropium,&#xD;
&#xD;
        3. salbutamol + RPL554,&#xD;
&#xD;
        4. ipratropium + RPL554,&#xD;
&#xD;
        5. RPL554&#xD;
&#xD;
        6. Placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate if RPL554 has an additive bronchodilator effect&#xD;
      when administered in combination with standard of care bronchodilators in patients with&#xD;
      COPD.This study investigates the pharmacodynamic effect of RPL554 using spirometry and whole&#xD;
      body plethysmography compared to placebo, when administered in addition to a beta2 agonist&#xD;
      (salbutamol), a muscarinic antagonist (ipratropium) or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>8 hour spirometry</measure>
    <time_frame>8 hours</time_frame>
    <description>Forced expired volume in one second (FEV1) over 8 hours post-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 hour spirometry</measure>
    <time_frame>12 hours</time_frame>
    <description>FEV1 over 4, 6 and 12 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body plethysmography</measure>
    <time_frame>4 hours</time_frame>
    <description>Functional residual capacity, residual volume, total lung capacity, specific airway conductance, specific airway resistance at 1 and 4 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>12 hours</time_frame>
    <description>AUC for RPL554 plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>12 hours</time_frame>
    <description>Cmax for RPL554 plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>12 hours</time_frame>
    <description>Tmax for RPL554 plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>Continuous measurement of adverse events throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory tests</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>Laboratory safety tests at screening, before each treatment and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>12 lead ECG at screening, before and up to 12 hours after each treatment and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>Blood pressure and pulse rate at screening, before and up to 12 hours after each treatment and end of study</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)</description>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium</intervention_name>
    <description>40 micrograms ipratropium administered using a pMDI</description>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554</intervention_name>
    <description>6 mg RPL554 administered using a nebuliser</description>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
    <arm_group_label>RPL554</arm_group_label>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol matched placebo</intervention_name>
    <description>Placebo pMDI</description>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium matched placebo</intervention_name>
    <description>Placebo pMDI</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>RPL554</arm_group_label>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554 matched placebo</intervention_name>
    <description>Nebulised placebo</description>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Salbutamol alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
          -  Males not donating sperm and using adequate contraception or females who are&#xD;
             surgically sterile or postmenopausal&#xD;
&#xD;
          -  12-lead ECG showing:Heart rate 45 to 90 bpm, QTcF≤450 msec, QRS ≤120 msec, PR interval&#xD;
             ≤220 msec, no clinically significant abnormality&#xD;
&#xD;
          -  Capable of complying with all study restrictions and procedures including ability to&#xD;
             use the study nebuliser correctly.&#xD;
&#xD;
          -  BMI 18 to 33 kg/m2 with a minimum weight of 45 kg.&#xD;
&#xD;
          -  COPD diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks&#xD;
&#xD;
          -  Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two&#xD;
             puffs of ipratropium) via spirometry:&#xD;
&#xD;
               -  Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of ≤0.70&#xD;
&#xD;
               -  Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal&#xD;
&#xD;
               -  ≥150 mL increase from pre-bronchodilator FEV1&#xD;
&#xD;
          -  Chest X-ray showing no abnormalities&#xD;
&#xD;
          -  Meet the concomitant medication restrictions and be expected to do so for the rest of&#xD;
             the study.&#xD;
&#xD;
          -  Smoking history of ≥10 pack years.&#xD;
&#xD;
          -  Capable of withdrawing from long acting bronchodilators throughout the study and short&#xD;
             acting bronchodilators for 8 hours prior to study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of life-threatening COPD including Intensive Care Unit admission and/or&#xD;
             requiring intubation.&#xD;
&#xD;
          -  COPD exacerbation requiring oral steroids in the previous 3 months&#xD;
&#xD;
          -  History of one or more hospitalisations for COPD in the previous 12 months&#xD;
&#xD;
          -  Respiratory tract infection (both upper and lower) treated with antibiotics in&#xD;
             previous 12 weeks&#xD;
&#xD;
          -  Evidence of cor pulmonale or clinically significant pulmonary hypertension.&#xD;
&#xD;
          -  Other respiratory disorders&#xD;
&#xD;
          -  Previous lung resection or lung reduction surgery.&#xD;
&#xD;
          -  Oral therapies for COPD in the previous 3 months and throughout the study.&#xD;
&#xD;
          -  Drug or alcohol abuse in the past 3 years&#xD;
&#xD;
          -  Received an experimental drug within 3 months or five half lives, whichever is longer.&#xD;
&#xD;
          -  Prior exposure to RPL554&#xD;
&#xD;
          -  Patients with a history of chronic uncontrolled disease that the Investigator believes&#xD;
             are clinically significant.&#xD;
&#xD;
          -  Documented cardiovascular disease in last 3 months&#xD;
&#xD;
          -  Major surgery, (requiring general anaesthesia) in the previous 6 weeks, or will not&#xD;
             have fully recovered from surgery, or planned surgery through the end of the study.&#xD;
&#xD;
          -  History of malignancy of any organ system within 5 years with the exception of&#xD;
             localised skin cancers (basal or squamous cell)&#xD;
&#xD;
          -  Clinically significant abnormal values for safety laboratory tests&#xD;
&#xD;
          -  A disclosed history, or one known to the Investigator, of significant non compliance&#xD;
             in previous investigational studies or with prescribed medications.&#xD;
&#xD;
          -  Requires oxygen therapy, even on an occasional basis.&#xD;
&#xD;
          -  Inability to adequately perform whole body plethysmography.&#xD;
&#xD;
          -  Any other reason that the Investigator considers makes the subject unsuitable to&#xD;
             participate.&#xD;
&#xD;
          -  Patients with known hypersensitivity to atropine or its derivatives, or to ipratropium&#xD;
             bromide, salbutamol or RPL554 or their excipients/components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

